XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
  Depression
  Neuropsychiatry
  Personality Disorders
  Bulimia
  Anxiety
   Phobia
   Panic Disorders
   Stress
   PTSD
   GAD
   Agoraphobia
   OCD
   Social Phobia
  Substance Abuse
  Suicide
  CFS
  Psychoses
  Child Psychiatry
  Learning-Disabilities
  Psychology
  Forensic Psychiatry
  Mood Disorders
  Sleep Disorders
  Peri-Natal Psychiatry
  Psychotherapy
  Anorexia Nervosa
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

GAD Channel
subscribe to GAD newsletter

Latest Research : Psychiatry : Anxiety : GAD

   DISCUSS   |   EMAIL   |   PRINT
Pregabalin Receives a Positive Opinion from CHMP for the Treatment of Generalized Anxiety Disorder in Adults
Jan 28, 2006, 12:37, Reviewed by: Dr. Priya Saxena

"The psychological and physical effects of GAD disrupt work and personal relationships and make it difficult to carry on with everyday activities. Accurate diagnosis of GAD is important since prolonged anxiety increases impairment and worsens the outcome of co-existing physical illnesses."

 
Pfizer Inc said that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending marketing authorization of LyricaŽ (pregabalin), a novel mechanism for the treatment of generalized anxiety disorder (GAD) in adults.

The CHMP's positive recommendation will be reviewed by the European Commission, which has authority to approve medicines for the European Union. Pfizer anticipates a final decision from the Commission in the coming months.

"Though GAD has been formally recognized by the medical community and is frequently associated with high levels of distress and impairment, the condition often goes undetected and untreated," said Dr. Joseph Feczko, Pfizer's chief medical officer. "It is estimated that only one-third of those who suffer from this condition seek treatment despite the significant impact on patient quality of life. We are pleased that the CHMP has recognized the potential therapeutic benefits of Lyrica in treating this serious medical condition."

GAD, which affects an estimated five percent of people at some point in their lives, is a psychiatric disorder characterized by excessive worry as well as physical symptoms such as poor sleep, fatigue, difficulty concentrating, irritability and restlessness. GAD affects slightly more women than men, and symptoms are often chronic and worsen during times of stress. GAD occurs more frequently in patients with chronic medical illnesses, particularly in connection with pain syndromes. The direct annual healthcare costs associated with GAD in Europe are approximately $1.5 billion.

"Despite frequent visits to their doctor, GAD patients are still very poorly treated." said Dr. Stuart Montgomery, Professor of Psychiatry, Imperial College School of Medicine, University of London. "The psychological and physical effects of GAD disrupt work and personal relationships and make it difficult to carry on with everyday activities. Accurate diagnosis of GAD is important since prolonged anxiety increases impairment and worsens the outcome of co-existing physical illnesses."

Lyrica has been approved for various neuropathic pain indications including peripheral neuropathic pain, diabetic and postherpetic neuropathic pain and adjunctive therapy for epilepsy in more than 50 countries outside of the United States. The most common adverse events in Lyrica's clinical development program were dizziness and somnolence. In the U.S., LyricaŽ (pregabalin) capsules C-V is FDA approved for the management of diabetic peripheral neuropathy, postherpetic neuralgia and adjunctive treatment of partial onset seizures. Developed by Pfizer, Lyrica is an alpha-2-delta ligand that is believed to work by calming hyper-excited neurons.
 

- Pfizer Inc.
 

Lyrica Full U.S. Prescribing Information

 
Subscribe to GAD Newsletter
E-mail Address:

 



Related GAD News

Pregabalin Receives a Positive Opinion from CHMP for the Treatment of Generalized Anxiety Disorder in Adults


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us